Wegovy Diarrhoea: Causes, Duration and Tips

Wegovy diarrhoea is one of the most commonly reported side effects of semaglutide, affecting more than one in ten people who take this weight-management medicine. Understanding why it happens, how long it typically lasts, and when to seek medical advice can make a significant difference to how well treatment is tolerated. This article explains the mechanism behind Wegovy-related diarrhoea, offers practical self-management strategies, highlights red-flag symptoms that require prompt medical attention, and clarifies what to expect as the dose increases over time.

Why does Wegovy cause diarrhoea?

Wegovy causes diarrhoea by activating GLP-1 receptors throughout the gut, slowing gastric emptying and disrupting fluid absorption in the bowel. This is classified as a very common side effect, occurring in more than one in ten users.

Wegovy (semaglutide) causes diarrhoea primarily by slowing gastric emptying and altering gut motility, effects that arise directly from its mechanism of action as a glucagon-like peptide-1 (GLP-1) receptor agonist.^[1][14] GLP-1 receptors are found throughout the gastrointestinal tract, and when semaglutide activates them, it reduces the speed at which food moves from the stomach into the small intestine.^[15][16] This change in transit time can disrupt normal fluid absorption in the bowel, leading to looser, more frequent stools.

The gut may also respond to semaglutide through changes in digestive hormone release, which can further affect stool consistency; however, the precise contribution of these additional mechanisms is not fully established and may vary between individuals.

Diarrhoea is classified as a very common side effect in the UK Wegovy Summary of Product Characteristics (SmPC), meaning it is reported in more than one in ten people who take the medicine. This classification is based on observed frequency in clinical trials rather than on the pharmacological explanation alone.

It is worth noting that diarrhoea tends to occur alongside other gastrointestinal effects such as nausea, vomiting, constipation and abdominal discomfort. These effects are generally most pronounced when treatment begins or when the dose is increased, reflecting the gut's adjustment to a new level of GLP-1 receptor stimulation. For most people, these symptoms are temporary rather than a sign that something has gone seriously wrong, though the red-flag features described later in this article should always be taken seriously.

How long does diarrhoea last when you start Wegovy?

Diarrhoea is usually transient, settling shortly after each new dose level is introduced, with symptoms most common during the escalation phase and declining once a stable dose is maintained.

For most people, diarrhoea associated with starting Wegovy is transient, typically settling within a short period after each new dose level is introduced, though individual experience varies and no single timeframe applies to everyone. The standard Wegovy dosing schedule, as set out in the UK SmPC, begins at 0.25 mg once weekly and escalates gradually over several months, reaching a maintenance dose of 2.4 mg once weekly. Each step up in dose can trigger a fresh, short-lived episode of gastrointestinal upset, including diarrhoea, as the gut adapts.

Clinical trial data from the STEP programme, which formed the basis of Wegovy's regulatory approval, showed that gastrointestinal side effects were most common during the dose-escalation phase and generally declined in frequency and severity once a stable dose was maintained.^[8][9] This pattern means that some people experience repeated but brief episodes of diarrhoea at each escalation step rather than one prolonged episode.

Individual experience varies considerably. Factors such as diet, hydration, pre-existing gut sensitivity and the pace of dose escalation can all influence how long symptoms persist. People who eat high-fat or high-sugar meals, or who consume alcohol, may find that diarrhoea is more troublesome, as these are commonly reported dietary triggers. If diarrhoea continues for more than a few weeks at a stable dose without any obvious dietary trigger, it is worth discussing this with a GP or prescribing clinician, as persistent symptoms may warrant further assessment rather than being attributed solely to the medication.

Managing Wegovy-related diarrhoea: practical tips

Eating smaller meals, avoiding high-fat and spicy foods, and staying well hydrated are the key strategies for managing Wegovy-related diarrhoea. Oral rehydration solutions can help replace lost electrolytes if symptoms are frequent.

Several practical measures can help reduce the frequency and severity of diarrhoea while taking Wegovy, and most centre on dietary adjustments and maintaining adequate hydration. Eating smaller, more frequent meals rather than large portions reduces the volume of food entering the gut at any one time, which can ease the burden on a digestive system already working more slowly than usual. Avoiding foods that are high in fat, very spicy or heavily processed is also advisable, as these are more likely to provoke loose stools.

Staying well hydrated is particularly important. Diarrhoea causes fluid and electrolyte losses, and dehydration can develop quickly, especially in warm weather or if vomiting is also present. Sipping water steadily throughout the day, rather than drinking large amounts at once, is generally better tolerated. Oral rehydration solutions available from pharmacies can help replace lost electrolytes if diarrhoea is frequent.

Other helpful strategies include:

• Reducing alcohol and caffeine intake, both of which can accelerate gut transit and worsen loose stools.

• Eating slowly and chewing food thoroughly to support digestion.

• Keeping a food and symptom diary to identify personal triggers.

• Avoiding lying down immediately after eating, which can worsen nausea and indirectly affect bowel habit.

Over-the-counter antidiarrhoeal medicines such as loperamide may provide short-term relief, but it is advisable to speak with a pharmacist or GP before using them regularly alongside Wegovy. Loperamide should be avoided if diarrhoea is accompanied by fever, blood or mucus in the stool, as these features require medical assessment rather than self-treatment.^[10][11]

Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where questions about managing side effects can be discussed as part of ongoing care.

When should you be worried about diarrhoea on Wegovy?

Seek medical advice if diarrhoea contains blood or mucus, is accompanied by severe abdominal pain, or persists for more than a week at a stable dose. Severe pain radiating to the back may indicate pancreatitis and requires urgent assessment.

Most diarrhoea associated with Wegovy is mild to moderate and resolves without medical intervention, but certain features should prompt prompt contact with a healthcare professional. Signs that warrant a call to your GP or, if out of hours, NHS 111 include diarrhoea that is severe, contains blood or mucus, is accompanied by significant abdominal pain, or persists for more than a week at a stable dose without an obvious dietary explanation.

Dehydration is the most common complication of prolonged diarrhoea and can become serious, particularly in older adults or people with kidney disease. Warning signs of dehydration include dark urine, dizziness, a dry mouth, reduced urination and feeling faint on standing.^[12] If these symptoms develop, contact your GP promptly. If someone becomes confused, cannot keep any fluids down, or shows signs of severe dehydration, this requires urgent assessment and you should call 999 or go to an accident and emergency department.

The UK Wegovy SmPC notes that acute pancreatitis has been reported in people taking semaglutide, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome.^[6][7] Pancreatitis can present with severe, persistent abdominal pain that may radiate to the back, sometimes accompanied by vomiting and diarrhoea.^[13][6] If this pattern of pain occurs, stop taking Wegovy and seek urgent medical attention.

Suspected side effects from Wegovy can be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. Reporting helps regulators monitor the safety of medicines in real-world use and contributes to ongoing post-marketing surveillance.

Does diarrhoea get better as your dose increases?

Diarrhoea often recurs briefly with each dose increase but typically settles as the gut adapts; many people find symptoms become less noticeable over time. If symptoms are severe, discuss slowing the escalation schedule with your prescribing clinician.

Diarrhoea does not consistently worsen with each Wegovy dose increase for everyone, but it is common for gastrointestinal symptoms, including diarrhoea, to recur transiently each time the dose steps up. The Wegovy dosing schedule escalates gradually, and this slow titration is specifically designed to allow the gut time to adapt and to minimise the severity of side effects at each new level. For many people, symptoms that appeared at a lower dose settle before the next increase is due.

The authorised Wegovy doses, as set out in the UK SmPC and confirmed by the MHRA, include strengths up to 2.4 mg once weekly, and the MHRA has also authorised a 7.2 mg strength. Whether diarrhoea becomes more or less troublesome at higher doses varies between individuals. Some people find that their gut adapts progressively and that symptoms become less noticeable over time, even as the dose rises. Others may find that each escalation brings a brief return of loose stools before settling again.

If diarrhoea at a particular dose level is severe enough to cause significant distress or dehydration, it is reasonable to discuss with your prescribing clinician whether the dose escalation schedule should be slowed. The UK Wegovy SmPC acknowledges that tolerability varies and supports the principle that the pace of titration may be adjusted based on individual response.^[1][2] Stopping Wegovy abruptly without medical advice is not recommended, as the decision to pause, slow or discontinue treatment should be made in consultation with a clinician who can weigh the benefits and risks in the context of your individual health.

Scientific References

1. Wegovy, INN-semaglutide – EPAR Product Information.
2. Package Leaflet: Information for the Patient – Wegovy (semaglutide).
3. GLP-1 receptor agonists: reminder of the potential side effects and to be aware of the potential for misuse.
4. Medicines regulator approves up to 7.2 mg dose of semaglutide/Wegovy for patients with obesity only.
5. Single-dose 7.2 mg semaglutide (Wegovy) pen approved to treat adult patients with obesity.
6. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis including necrotising and fatal cases.
7. Ozempic 0.5 mg solution for injection in pre-filled pen – SmPC.
8. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).
9. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss (STEP 1–3 pooled).
10. Loperamide – Who can and cannot take loperamide.
11. Loperamide Hydrochloride 2 mg Capsules – Patient Information Leaflet.
12. Dehydration.
13. Acute pancreatitis.
14. GLP-1 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management.
15. Neglected GLP-1 receptors in the eyes and nose: possible correlation with regulation of appetite.
16. Exendin-4 imaging based on gastrointestinal GLP-1R targets for IBD diagnosis and efficacy assessment.
17. Semaglutide: a medicine to manage type 2 diabetes or obesity.
18. Semaglutide – BNF.

Frequently Asked Questions